A K Nooka

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

A K Nooka, Jonathan L. Kaufman, Samatha Muppidi et al. · Leukemia · 2013 · 191 citations

Hematological Malignancy, Oncology, High-risk Myeloma Patients +6

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Sergio Giralt, Laurent Garderet, Brian G.M. Durie et al. · Biology of Blood and Marrow Transplantation · 2015 · 162 citations · Full text

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Shannon M. Matulis, Vikas A. Gupta, A K Nooka et al. · Leukemia · 2015 · 132 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Autoimmune Disease +8

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax

Richa Bajpai, Shannon M. Matulis, Changyong Wei et al. · Oncogene · 2015 · 98 citations · Full text

Hematological Malignancy, Glutamine Metabolism, Medicine +10

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

Paul G. Richardson, Craig C. Hofmeister, Noopur Raje et al. · Leukemia · 2017 · 34 citations · Full text